Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.

Inclusion Criteria: \- Patients who meet ROME-4 diagnostic criteria for cannabinoid hyperemesis syndrome Exclusion Criteria: * Already on dopamine agonist/antagonist therapy for another condition * Parkinson's disease * Lewy body dementia * Men with QTc \> 450 * Women with QTc \> 460 * Patients with documented allergy to haloperidol * Patients with known functional prolactinomas * Patients who are breastfeeding * Patients under the age of 18 * Patients who are pregnant * Patients who are in the prison system * Patients who are unable to consent